Descripción del proyecto
La primera terapia celular de su categoría para tumores sólidos
Casi una tercera parte de los cánceres de ovario desarrollan resistencia a los fármacos quimioterapéuticos que contienen platino, como el cisplatino y el carboplatino. El equipo del proyecto MACOV, financiado por el Consejo Europeo de Innovación, pretende abordar esta cuestión médica a través del desarrollo de un enfoque inmunoterápico basado en macrófagos. La idea es generar un producto listo para usar compuesto por macrófagos alogénicos portadores de tratamientos dirigidos a células cancerosas. En el proyecto se investigará la eficacia de estas células en múltiples modelos animales de cáncer de ovario resistente al platino. Además, los investigadores estudiarán la farmacocinética y farmacodinámica de este producto celular y, junto con la evaluación toxicológica, prepararán un ensayo clínico de fase I.
Objetivo
Resistance to platinum-based chemotherapy is a major clinical challenge in ovarian cancer. About 300,000 women are diagnosed with ovarian cancer each year and the number of deaths is estimated at 180,000 worldwide each year. Ovarian cancer metastasizes early in its development, often before it's diagnosed. Ovarian cancer treatment involves surgery with frontline platinum-based chemotherapy. As many as 15-30% of patients with ovarian cancer have primary platinum-resistant or refractory disease. The recurrence of ovarian cancer is now considered a sign of an incurable disease (it becomes platinum-resistant).
The project MACOV aims to develop an innovative allogeneic, “ready-to-use” macrophage-based therapy for platinum-resistant ovarian cancer. This is a ground-breaking, first in class therapy that shows very high efficacy in multiple solid tumors of unmet medical need.
These cells are equipped with targeted therapy drugs complexed with the carrier protein ensuring their stability in the carrier cell. The protein-drug complex is transferred specifically to cancer cells. The whole concept of this cell therapy is based on the groundbreaking scientific discoveries of MDC (Macrophage-Drug Conjugate). Two European Research Council (ERC) grants were received to study the molecular basis of the discovered mechanism - in 2016 and 2020. In 2018 this project was selected to be promoted as one of the 10 European projects during ERC 10th Anniversary.
The MACOV project will generate of complete efficacy data package for the pre-clinical development of MDC-735 product, consisting of efficacy in multiple animal models for platinum-resistant ovarian cancer, PK, PD and toxicology study as well as consolidate IP and validate business case. The result of the project will be a validated cell therapy product for platinum-refractory ovarian cancer, tested for effectiveness and ready-to-use for the Phase I clinical trial.
Ámbito científico
Programa(s)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Convocatoria de propuestas
HORIZON-EIC-2022-TRANSITION-01
Consulte otros proyectos de esta convocatoriaRégimen de financiación
HORIZON-AG - HORIZON Action Grant Budget-BasedCoordinador
01-510 WARSAW
Polonia
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.